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Cognitive deficits are increasingly acknowledged as a highly relevant clinical feature of 
schizophrenia, susceptible of therapeutic intervention. Considerable efforts have been devoted 
to identify and develop pharmacological agents that provide cognitive-enhancing benefits 
to patients with schizophrenia. However, results from studies are not univocal and the “real 
world” cognitive functioning gain provided by these agents seems disappointingly modest. 
Three issues are crucial in this respect. First, there is no convincing evidence that atypical 
agents are any better than typical agents in improving cognitive functioning. Second, even 
though studies observe statistically significant treatment effects on cognition, these gains are 
poor or imperceptible on a clinical and functional level. Third, studies do not report differences 
in treatment effect compared to placebo effect in terms of their cognitive enhancing effects. 
Finally, examples of interventions that do provide important and meaningful improvements in 
cognitive functioning in schizophrenia patients will be briefly presented.
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2009). Thus, Harvey (2009) concludes a recent, comprehensive 
review of the literature in the following way: “Although potential 
pharmacological targets have been identified, previous results have 
been disappointing across multiple treatment targets. Optimism 
should arise from the findings that cognitive remediation inter-
ventions improve both cognitive performance and functional out-
comes” (p. 333). This conclusion rings particularly important also 
in terms of strategic resource allocation, since the generalization of 
cognitive/metacognitive-based interventions at the level of men-
tal health service delivery seems currently to be the most robust 
evidence-based option to target cognitive functioning.
Three further issues, which will be discussed below, are crucial 
in this respect. First, there is no convincing evidence that atypical 
agents are any better than typical agents in improving cognitive 
functioning. Second, even though studies observe statistically sig-
nificant treatment effects on cognition, these gains are poor or 
imperceptible on a clinical and functional level. Third, studies do 
not report differences in treatment effect compared to placebo 
effect in terms of their cognitive enhancing effects.
Typical versus aTypical neurolepTic TreaTmenT
Systematic study of the effects of atypical (or second generation) 
neuroleptics on the neuropsychological deficits in schizophrenia 
began in the early 1990s with the idea that these medications might 
improve certain aspects of neurocognitive functioning, especially 
when compared with first generation (or typical) neuroleptics. 
However, studies do not seem to point to a particular drug or group 
of drugs that are more effective in enhancing cognitive impairment 
in schizophrenia patients and this, in particular, when comparing 
atypical and typical neuroleptics. Furthermore, Heinrichs (2007) 
inTroducTion
Cognitive deficits are increasingly being acknowledged as an impor-
tant feature of schizophrenia (Heinrichs, 2005) and, hence, as a 
potential therapeutic target. Moderate to severe cognitive impair-
ment is frequently observed in schizophrenia both in early and 
chronic phases with a substantial impact on the global functional 
impairment and the long-term outcome (Kraus and Keefe, 2007). 
In this respect, a recent review of 16 longitudinal studies (Green and 
Nuechterlein, 2004) confirmed that cognition can reliably predict 
long-term outcome with medium to large effect sizes (0.5–0.8 or 
higher). Such findings spurred the United States National Institute 
of Mental Health to target cognitive deficits and boosted the search 
for ad hoc pharmacological intervention (cf. Marder and Fenton, 
2004; Kraus and Keefe, 2007).
However, despite the considerable financial and research efforts 
that have been devoted to identify and develop pharmacological 
agents, there seems to be little evidence of significant cognitive-
enhancing benefits for the current compounds. Indeed, results from 
Randomized Controlled Trial (RCT) studies are not univocal and 
the “real world” cognitive functioning gain provided by these agents 
seems disappointingly modest or, at least, of problematic “bench 
to bedside” translation.
Following this line, Green (2007) has remarked that we are 
becoming “less comfortable with pinning our hopes on antipsy-
chotic medications as a way to achieve cognitive improvement” 
(p. 992). Quite on the contrary, alternative intervention strategies, 
such as cognitive/metacognitive-based ones, resulted more effective 
in empowering cognitive skills with long-lasting and meaningful 
improvements on social and professional functioning (cf. Wexler 
and Bell, 2005; Moritz and Woodward, 2007; Medalia and Choi, Frontiers in Psychology  |  Psychopathology    September 2010  | Volume 1  | Article 158  |  2
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However, these studies involved few patients (no study enrolled 
more than 36 patients). More recently, a large (N = 250) double-
blind placebo-controlled trial on donepezil (Keefe et al., 2008) pro-
vided evidence of a larger placebo compared to treatment effect. 
When compared with the placebo treatment group, donepezil was 
not more effective for the improvement of cognitive impairment 
in schizophrenia patients. Furthermore, although both treatment 
groups experienced mild cognitive test performance improvement, 
the effect size of cognitive improvement was found to be markedly 
higher in the placebo group (0.45) compared to the donepezil group 
(0.26). Furthermore, the placebo group showed statistically greater 
improvement than the donepezil group at follow-up (12 weeks). 
This led the authors to suggest that, based on diminished practice-
induced learning relative to the placebo group, donepezil treatment 
might have exerted a negative influence on cognition.
conclusions
Despite wide-spread optimism, available pharmacological agents do 
not seem to provide substantial cognitive-enhancing effects other 
than the symptomatic benefit on the major, conventional psycho-
pathological dimensions of schizophrenia. In this respect, three core 
issues deserve critical consideration and which hopefully will also 
be addressed in future studies. First, despite the enormous resources 
used to develop atypical agents, there is no convincing evidence that 
these are any better than typical agents in improving cognitive func-
tioning. Thus, although atypical agents may provide more favorable 
profiles in terms of compliance and overall clinical management, 
there is till now no robust evidence that these agents have a par-
ticular and appreciable advantage in terms of improving cognitive 
functioning. Second, even though studies (whether they are study-
ing typical or atypical agents) find statistically significant treatment 
effects on cognition, these gains are poor or almost impalpable on a 
clinical and functional level. Furthermore, due to time constraints in 
the experimental designs, we seriously lack crucial information on 
the stability of the long-term effects on cognition. Future research 
needs to critically and specifically address the size and the temporal 
profile of the cognitive gains on a clinical and functional level. Third, 
and perhaps more fundamental, studies show that there is little 
difference (in terms of cognitive-enhancement) even compared to 
placebo: one study (Keefe et al., 2008) even showed a better cogni-
tive improvement in the placebo group. Thus, for example, future 
(double-blind, placebo-controlled) studies will need to explore, in 
a more direct and critical manner, whether or not certain agents are 
actually having a negative effect on cognitive functioning in patients 
with schizophrenia.
For the time being, available pharmacological agents seem to 
provide modest (if any) appreciable cognitive benefits to patients 
suffering from schizophrenia. Furthermore, there seems to be rather 
scarce evidence of any direct specific cognitive-enhancing effect 
other than those secondary to a global deflation of the severity of 
psychopathology. In this respect, it seems reasonable to hypothesize 
that more resources – both financial and human – might be bet-
ter off invested in complementary treatment schemes (e.g., cogni-
tive remediation, vocational training, metacognitive training) that 
do provide important, direct, and meaningful improvements for 
patients. Indeed, a number of approaches to remediating   cognition 
in  schizophrenia  have  been  developed  and  studied  in  the  last 
15 years and this literature has been reviewed in six   meta-analytic 
concludes that cognitive deficits in patients with schizophrenia 
appear for the most part unresponsive to antipsychotic medication 
and this regardless of the type of drug. Mishara and Goldberg (2004) 
have shown that the presumed superiority of atypical neuroleptics 
in enhancing cognition was absent in a large patient sample when 
compared to typical neuroleptics. In a recent article summarizing 
the findings of the Clinical Antipsychotic Trials in Intervention 
Effectiveness (CATIE) study, the authors confirm that there were 
no significant differences between the first and second generation 
neuroleptics in terms of changes in cognitive domains (Keefe et al., 
2007). Furthermore, as noted by Palmer et al. (2009), while overall 
changes in each of the groups were statistically significant, they were 
small and of questionable functional importance and (especially in 
the absence of an untreated group) could at least partially reflect 
practice effects. Moreover, upon further inspection, findings in 
this study suggest that the first generation agents actually revealed 
greater improvement compared to the second generation agents. 
Finally, a more recent trial also suggests no differential cognitive 
benefit of second generation versus first generation neuroleptics 
(Davidson et al., 2009). Thus, not only do studies fail to point 
to a particular drug or group of drugs that are more effective in 
enhancing cognitive impairment in schizophrenia but, in the light 
of the modest documented effect sizes, “there appears little reason 
to be very enthusiastic about the cognitive benefits of either class 
of medication” (Palmer et al., 2009, p. 376).
TreaTmenT effecT versus learning effecT
In studies that have shown cognitive benefits, the effect sizes are 
often small and probably of little (or no) clinical significance. 
Heinrichs (2007) re-examined the treatment benefits (by com-
paring raw test scores at baseline and following 2 months) of the 
CATIE study (Keefe et al., 2007), revealing that patients’ recall 
of a 12-noun word list improved, on average, by one-tenth of a 
word during this period. Further, word production on a verbal 
fluency task improved by an average of three-tenths of an addi-
tional word, and there were 1.5 fewer perseverative errors on the 
64-card version of the Wisconsin Card Sorting test. Thus, even 
if studies reveal cognitive improvements, the benefits are small, 
and it is doubtful that they will have an impact on a clinical, 
social, or vocational level. What is more, these slight cognitive 
improvements may simply be attributed to a test–retest (learning) 
effect. Such a learning effect might magnify statistical differences 
in laboratory performances, but it is quite unlikely to offer any 
meaningful clinical proxy of daily life functioning. Finally, cogni-
tive benefits were only evaluated after 2 months of treatment and 
thus the long-term benefits are not known. This unfortunately 
compromises the possibility of truly assessing the clinical impact 
in terms of enduring benefits.
TreaTmenT effecT versus placebo effecT
When  studies  have  included  a  placebo  group,  however,  the 
findings are even more dramatic. Four previous double-blind, 
placebo-  controlled trials (Friedman et al., 2002; Tugal et al., 2004; 
Freudenreich et al., 2005; Fagerlund et al., 2007) observed that 
change in cognitive functioning when given donepezil (a cholineste-
rase inhibitor) did not significantly differ from the change observed 
when given placebo. Similar negative results have been observed for 
other agents such as Modafinil (Freudenreich et al., 2009).www.frontiersin.org  September 2010  | Volume 1  | Article 158  |  3
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2006; Penn et al., 2008). At present, however, social cognition has 
not been shown to be amenable to enhancement via antipsychotic 
medication (Penn et al., 2008).
Needless to say, these two approaches to treatment and rehabili-
tation (namely pharmacotherapy and cognitive-based intervention 
strategies) are highly complementary and are usually combined 
in clinical reality. However, in order to maximize the benefits for 
patients, it is important to optimize the balance between these 
two intervention strategies according to the specific domains that 
require therapeutic empowerment. Future studies should further-
more address the combination of cognitive and pharmacological 
treatment schemes that provide the widest and more enduring 
benefits for the patients.
studies. With the exception of one (Pilling et al., 2002), all have 
found moderate to large effect sizes (Kurtz et al., 2001; Suslow 
et al. 2001; Krabbendam and Aleman, 2003; Twamley et al. 2003; 
McGurk et al. 2007) – effect sizes far greater than those observed for 
any drug treatment. Also, these remediation effects are durable up 
to at least 6 months after the interventions are withdrawn. Finally, 
and most importantly, these neuropsychological gains translate to 
improvements in real-world activities (Larøi and Van der Linden, 
2007; Levaux et al., 2009; Medalia and Choi, 2009). Similarly, cogni-
tive remediation programmes address prominent, complementary 
functional domains such as social cognition – and studies have 
furthermore observed beneficial effects on functional outcome 
measures in patients post-treatment (for reviews see Couture et al., 